Author: admin
Context Therapeutics and Integral Molecular Enter Collaboration and License Deal for Novel Claudin 6 Antibodies for Gynecologic Cancer Therapeutic Program
PHILADELPHIA, PA—APRIL 8, 2021—Context Therapeutics, a clinical-stage women’s oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and […]
Integral Molecular Enables Rapid Resistance Testing of Vaccines and Drugs Against Emerging Coronavirus Variants
PHILADELPHIA — In response to the evolving COVID-19 pandemic, Integral Molecular has adapted its SARS-CoV-2 reporter virus particle (RVP) technology to reflect emerging virus […]
Integral Molecular Announces Best-in-Class Antibodies Against Complex Oncology Target Claudin 18.2
PHILADELPHIA – Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces fully optimized, high-affinity lead monoclonal antibodies (MAbs) against Claudin 18.2 […]
Integral Molecular Partners with China’s Leading Preclinical CRO JOINN for Comprehensive Specificity Testing of Antibodies and CAR-T Therapeutics
PHILADELPHIA – JOINN Laboratories, China’s leading preclinical contract research organization (CRO), has partnered with Integral Molecular to provide researchers in China with rapid antibody […]